IL134982A - Antibodies that react with variant polypeptides of CD-44 surface proteins of cancer metastatic cells and their prepared diagnostic and pharmaceutical preparations - Google Patents

Antibodies that react with variant polypeptides of CD-44 surface proteins of cancer metastatic cells and their prepared diagnostic and pharmaceutical preparations

Info

Publication number
IL134982A
IL134982A IL13498291A IL13498291A IL134982A IL 134982 A IL134982 A IL 134982A IL 13498291 A IL13498291 A IL 13498291A IL 13498291 A IL13498291 A IL 13498291A IL 134982 A IL134982 A IL 134982A
Authority
IL
Israel
Prior art keywords
aca
gaa
cat
acc
cag
Prior art date
Application number
IL13498291A
Other languages
English (en)
Hebrew (he)
Original Assignee
Forschungsentrum Karlsurhe Gmb
Krebsforschungzentrum
Univ Karlsruhe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungsentrum Karlsurhe Gmb, Krebsforschungzentrum, Univ Karlsruhe filed Critical Forschungsentrum Karlsurhe Gmb
Publication of IL134982A publication Critical patent/IL134982A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13498291A 1990-05-07 1991-05-02 Antibodies that react with variant polypeptides of CD-44 surface proteins of cancer metastatic cells and their prepared diagnostic and pharmaceutical preparations IL134982A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4014510A DE4014510A1 (de) 1990-05-07 1990-05-07 Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
IL9802491A IL98024A (en) 1990-05-07 1991-05-02 Proteins of CD-44 surfaces, DNA sequences encoded by them and polypeptides encoded by said DNA sequences

Publications (1)

Publication Number Publication Date
IL134982A true IL134982A (en) 2004-05-12

Family

ID=6405813

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13498291A IL134982A (en) 1990-05-07 1991-05-02 Antibodies that react with variant polypeptides of CD-44 surface proteins of cancer metastatic cells and their prepared diagnostic and pharmaceutical preparations
IL9802491A IL98024A (en) 1990-05-07 1991-05-02 Proteins of CD-44 surfaces, DNA sequences encoded by them and polypeptides encoded by said DNA sequences
IL13498200A IL134982A0 (en) 1990-05-07 2000-03-09 Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL9802491A IL98024A (en) 1990-05-07 1991-05-02 Proteins of CD-44 surfaces, DNA sequences encoded by them and polypeptides encoded by said DNA sequences
IL13498200A IL134982A0 (en) 1990-05-07 2000-03-09 Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith

Country Status (21)

Country Link
US (3) US5506119A (zh)
EP (1) EP0531300B1 (zh)
JP (1) JP3133062B2 (zh)
KR (1) KR0184691B1 (zh)
AT (1) ATE106943T1 (zh)
AU (1) AU646858B2 (zh)
BR (1) BR1100650A (zh)
CA (1) CA2082382C (zh)
DE (2) DE4014510A1 (zh)
DK (1) DK0531300T3 (zh)
FI (1) FI106128B (zh)
HU (1) HU218905B (zh)
IE (1) IE62096B1 (zh)
IL (3) IL134982A (zh)
NO (3) NO309770B1 (zh)
NZ (1) NZ238056A (zh)
PT (1) PT97574B (zh)
TW (1) TW212202B (zh)
WO (1) WO1991017248A1 (zh)
YU (1) YU49126B (zh)
ZA (1) ZA913389B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002873A (en) * 1989-03-17 1991-03-26 Fred Hutchinson Cancer Research Center DNA sequence encoding a lymphocyte adhesion receptor for high endothelium
US5443750A (en) * 1991-01-16 1995-08-22 The Procter & Gamble Company Detergent compositions with high activity cellulase and softening clays
DE4134982A1 (de) * 1991-10-23 1993-04-29 Kernforschungsz Karlsruhe Verwendung von antikoerper enthaltenden praeparationen zur immunsuppression
WO1994002633A1 (en) * 1992-07-21 1994-02-03 Isis Innovation Limited Diagnostic method
CA2165461A1 (en) 1993-06-18 1995-01-05 Sirpa Jalkanen Compositions and diagnostic methods using monoclonal antibodies against cd44v6
DE4320623C2 (de) * 1993-06-22 1997-11-20 Boehringer Ingelheim Int Verfahren zur Diagnose und Analyse von Adenokarzinomen
DE4320624A1 (de) * 1993-06-22 1995-02-09 Boehringer Ingelheim Int Verfahren zur Diagnose und Analyse von Mammakarzinomen
EP0767379A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Kolonkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
DE19540515C1 (de) * 1995-10-31 1997-02-06 Boehringer Ingelheim Int Tumortherapie durch adoptiven Transfer CD44v-spezifischer zytotoxischer T-Lymphozyten
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
DE10026833A1 (de) * 2000-05-30 2001-12-13 Karlsruhe Forschzent Verfahren zur Identifizierung von Verbindungen zur Modulierung der Aktivität eines Tumorsuppressorgens
WO2004024750A2 (en) * 2002-09-13 2004-03-25 Dyax Corporation Cd44-binding ligands
DK2886126T3 (en) 2013-12-23 2017-09-18 Exchange Imaging Tech Gmbh Nanoparticle conjugated to CD44-binding peptides
CN109608536B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用
CN109608537B (zh) * 2018-12-12 2020-09-15 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5108904A (en) * 1990-03-26 1992-04-28 Alan Landay CD44 as a marker for HIV infection

Also Published As

Publication number Publication date
IE911526A1 (en) 1991-11-20
DE4014510A1 (de) 1991-11-14
DE59101889D1 (de) 1994-07-14
IL134982A0 (en) 2001-05-20
NO20001668D0 (no) 2000-03-31
ZA913389B (en) 1992-03-25
IE62096B1 (en) 1995-01-11
PT97574A (pt) 1992-01-31
CA2082382A1 (en) 1991-11-08
CA2082382C (en) 2008-09-30
EP0531300A1 (de) 1993-03-17
AU646858B2 (en) 1994-03-10
US5506119A (en) 1996-04-09
BR1100650A (pt) 2000-08-08
YU79491A (sh) 1994-06-10
NO20001668L (no) 1993-05-06
NO310661B1 (no) 2001-08-06
NO317154B1 (no) 2004-08-30
HU218905B (hu) 2000-12-28
NO924234L (no) 1993-01-04
DK0531300T3 (da) 1994-10-10
NO980293L (no) 1993-01-04
JPH05508309A (ja) 1993-11-25
US5885575A (en) 1999-03-23
FI925043A0 (fi) 1992-11-06
KR0184691B1 (ko) 1999-04-01
NO309770B1 (no) 2001-03-26
TW212202B (zh) 1993-09-01
JP3133062B2 (ja) 2001-02-05
US5760178A (en) 1998-06-02
HU9203449D0 (en) 1993-01-28
IL98024A0 (en) 1992-06-21
YU49126B (sh) 2004-03-12
PT97574B (pt) 1998-08-31
AU7565991A (en) 1991-11-27
FI106128B (fi) 2000-11-30
NO980293D0 (no) 1998-01-23
HUT63652A (en) 1993-09-28
NZ238056A (en) 1993-01-27
IL98024A (en) 2001-06-14
WO1991017248A1 (de) 1991-11-14
ATE106943T1 (de) 1994-06-15
NO924234D0 (no) 1992-11-04
FI925043A (fi) 1992-11-06
EP0531300B1 (de) 1994-06-08

Similar Documents

Publication Publication Date Title
IL134982A (en) Antibodies that react with variant polypeptides of CD-44 surface proteins of cancer metastatic cells and their prepared diagnostic and pharmaceutical preparations
JP4327350B2 (ja) エピトープへの結合能力を保持する結合部位ドメインの同定のための新規方法
US7132099B2 (en) Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US7259247B1 (en) Anti-human T-cell costimulating polypeptide monoclonal antibodies
US7786047B2 (en) Immunoglobulins devoid of light chains
CA2163012C (en) Anti-egfr single-chain fvs and anti-egfr antibodies
CN101379083A (zh) 诱导凋亡的蛋白质复合物以及其治疗应用
JP4776845B2 (ja) ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
JP2001513794A (ja) 特定の腫瘍の治療および免疫反応を抑制するための、抗−ｃｄ４４抗体含有調製物の使用
JPH11510375A (ja) ペプチド−ｍｈｃ複合体を指向するファージディスプレイライブラリーからの組換え抗体
WO1995015340A1 (en) Monoclonal antibodies to antigens expressed by human dendritic cells
EP0503646A1 (en) Monoclonal antibodies recognizing lymphocyte function associated antigen-3
WO1991010722A2 (en) Chimeric immunoglobulin for cd4 receptors
FI106129B (fi) Menetelmät valmistaa muuntuneita CD44-pintaproteiineja ja näitä proteiineja vastaan vaikuttavia vasta-aineita
JPH06327491A (ja) マウス細胞表面抗原に対するハムスターモノクローナル抗体
Yamashita et al. Tissue-specific and growth-regulated expression of CD44 variable exon determinants in the mouse
JPS63233922A (ja) 抗イディオタイプｔ細胞ハイブリドーマ

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees